Roger Li

3.3k total citations
173 papers, 1.6k citations indexed

About

Roger Li is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Roger Li has authored 173 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Surgery, 49 papers in Pulmonary and Respiratory Medicine and 30 papers in Oncology. Recurrent topics in Roger Li's work include Bladder and Urothelial Cancer Treatments (113 papers), Urinary and Genital Oncology Studies (66 papers) and Urological Disorders and Treatments (23 papers). Roger Li is often cited by papers focused on Bladder and Urothelial Cancer Treatments (113 papers), Urinary and Genital Oncology Studies (66 papers) and Urological Disorders and Treatments (23 papers). Roger Li collaborates with scholars based in United States, Italy and Canada. Roger Li's co-authors include Ashish M. Kamat, Colin P. Dinney, Scott M. Gilbert, D. Duane Baldwin, Firas G. Petros, Muhannad Alsyouf, Michelle Lightfoot, Neema Navai, Philippe E. Spiess and Rosanne Santos and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roger Li

152 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Li United States	22	898	578	303	299	284	173	1.6k
Bodil Laub Petersen Denmark	26	539 0.6×	313 0.5×	91 0.3×	296 1.0×	563 2.0×	65	1.8k
Hans‐Helge Seifert Switzerland	24	354 0.4×	772 1.3×	409 1.3×	256 0.9×	751 2.6×	76	1.8k
José Rubio Spain	17	631 0.7×	258 0.4×	271 0.9×	124 0.4×	144 0.5×	38	1.0k
Olaf Reich Austria	25	606 0.7×	244 0.4×	131 0.4×	515 1.7×	370 1.3×	110	2.3k
Suhail Baithun United Kingdom	24	863 1.0×	298 0.5×	159 0.5×	471 1.6×	265 0.9×	67	1.6k
Beatriz Lifschitz‐Mercer Israel	21	499 0.6×	388 0.7×	112 0.4×	248 0.8×	389 1.4×	73	1.5k
R. Harzmann Germany	19	450 0.5×	1.1k 1.8×	123 0.4×	279 0.9×	161 0.6×	94	1.6k
Alain Le Duc France	21	354 0.4×	672 1.2×	299 1.0×	116 0.4×	189 0.7×	42	1.3k
Christine Mian Italy	27	1.6k 1.8×	264 0.5×	615 2.0×	328 1.1×	424 1.5×	77	2.2k
James Scurry Australia	27	1.1k 1.2×	111 0.2×	259 0.9×	200 0.7×	270 1.0×	98	2.0k

Countries citing papers authored by Roger Li

Since Specialization

Citations

This map shows the geographic impact of Roger Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Li more than expected).

Fields of papers citing papers by Roger Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Li. The network helps show where Roger Li may publish in the future.

Co-authorship network of co-authors of Roger Li

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Li. A scholar is included among the top collaborators of Roger Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Li. Roger Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tyson, Mark D., et al.. (2025). BOND-003- COHORT P: A MULTI-NATIONAL, SINGLE-ARM STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC FOR THE TREATMENT OF HIGH-RISK, PAPILLARY ONLY, BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars and Original Investigations. 43(3). 50–51. 2 indexed citations

Jong, Joep J. de, Siamak Daneshmand, Robert S. Svatek, et al.. (2025). Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. European Urology Open Science. 73. 24–30. 1 indexed citations

Li, Roger, Gautam Jayram, Angela Girvin, et al.. (2025). MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER. Urologic Oncology Seminars and Original Investigations. 43(3). 53–53.

Song, Xiaofei, Xiaoqing Yu, Carlos Moran Segura, et al.. (2025). ROICellTrack: a deep learning framework for integrating cellular imaging modalities in subcellular spatial transcriptomic profiling of tumor tissues. Bioinformatics. 41(5). 1 indexed citations

Cheng, Liang, et al.. (2025). Recent advances in liquid biopsy for genitourinary cancers: A narrative review. Histopathology. 88(1). 338–352.

Li, Roger, Luigi Nocera, Kyle Rose, et al.. (2024). Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. European Urology Oncology. 7(3). 614–624. 8 indexed citations

Gould, Billie, Prithvi Murthy, Kyle Rose, et al.. (2024). Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).. Journal of Clinical Oncology. 42(16_suppl). 4600–4600.

Jong, Joep J. de, Siamak Daneshmand, Robert S. Svatek, et al.. (2024). A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy. British Journal of Urology. 135(4). 648–656. 1 indexed citations

Posada, Jessica M., Evgeny Yakirevich, Ashish M. Kamat, et al.. (2024). Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Modern Pathology. 37(3). 100424–100424. 8 indexed citations

10.

Li, Roger, et al.. (2023). Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients’ access to novel therapeutics. Urologic Oncology Seminars and Original Investigations. 41(9). 390.e1–390.e17. 1 indexed citations

11.

Rose, Kyle, Joshua J. Meeks, Bishoy M. Faltas, et al.. (2023). Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nature Reviews Urology. 20(7). 406–419. 27 indexed citations

12.

Rose, Kyle, Joshua J. Meeks, Bishoy M. Faltas, et al.. (2023). Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nature Reviews Urology. 20(7). 452–452. 2 indexed citations

13.

Li, Roger, Wade J. Sexton, Jasreman Dhillon, et al.. (2023). A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clinical Cancer Research. 29(19). 3875–3881. 18 indexed citations

14.

Li, Roger, et al.. (2021). Sperm Sizer: a program to semi-automate the measurement of sperm length. Behavioral Ecology and Sociobiology. 75(5). 9 indexed citations

15.

Matulay, Justin T., Roger Li, Patrick J. Hensley, et al.. (2021). Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. The Journal of Urology. 205(6). 1612–1621. 42 indexed citations

16.

Hensley, Patrick J., Kelly K. Bree, Nathan A. Brooks, et al.. (2021). Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. British Journal of Urology. 128(5). 634–641. 8 indexed citations

17.

Petros, Firas G., Roger Li, Bryan Fellman, et al.. (2019). Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 37(6). 354.e19–354.e26. 4 indexed citations

18.

Li, Roger, Michael Metcalfe, William Tabayoyong, et al.. (2018). Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. European Urology Oncology. 2(3). 286–293. 9 indexed citations

19.

Keheila, Mohamed, Michelle Lightfoot, Jim Shen, et al.. (2017). Predictors of narcotic use after percutaneous nephrolithotomy.. PubMed. 24(1). 8634–8640. 4 indexed citations

20.

Metcalfe, Michael, James E. Ferguson, Roger Li, et al.. (2017). Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus. 3(6). 577–583. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact